Skip to main content
. 2011 Jan 27;96(5):775–778. doi: 10.3324/haematol.2010.029678

Figure 2.

Figure 2.

Expression of TET2 in controls and PV patients during in vitro maturation of erythroid progenitors. (A) Controls; unaffected subjects. (B) Sporadic PV subjects with JAK2V617F mutation without known TET2 mutations. (C) P1–P4 PV subjects with TET2 and JAK2V617F mutations.